Status:
WITHDRAWN
SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer
Lead Sponsor:
Adaptimmune
Conditions:
Head and Neck Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is a study to investigate the efficacy and safety of ADP-A2M4 in combination with pembrolizumab in HLA-A\*02 eligible and MAGE-A4 positive subjects with recurrent or metastatic Head and Neck canc...
Eligibility Criteria
Inclusion
- Key Inclusion Criteria
- Age ≥18 and \<75 years
- Diagnosis of head and neck squamous cell carcinoma with metastatic or unresectable, recurrent disease. confirmed by histology cytology.
- Checkpoint inhibitor naïve and indicated for pembrolizumab or currently receiving pembrolizumab (monotherapy). May have received prior platinum containing chemotherapy regimen or checkpoint inhibitor therapy.
- Subjects that have already received pembrolizumab (alone or in combination) and are progressing or have completed immune checkpoint inhibitor therapy for recurrent/metastatic disease, may still be enrolled and will skip Part A of the study.
- These subjects will enroll into Part B when manufactured T cells are available.
- Measurable disease according to RECIST v1.1.
- HLA-A\*02 positive by central laboratory.
- Tumor shows MAGE-A4 expression confirmed by central laboratory.
- ECOG Performance Status of 0 or 1.
- Left ventricular ejection fraction (LVEF) ≥50%.
- Note: other protocol defined Inclusion criteria may apply
- Key Exclusion Criteria:
- Positive for any HLA-A\*02 allele other than: one of the inclusion alleles, HLA- A\*02:07P or HLA-A\*02 null alleles
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study or history of severe hypersensitivity to another monoclonal antibody.
- History of autoimmune or immune mediated disease
- Leptomeningeal disease, carcinomatous meningitis or CNS metastases.
- Other prior malignancy that is not considered by the Investigator to be in complete remission
- Clinically significant cardiovascular disease
- Uncontrolled intercurrent illness
- Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus
- Pregnant or breastfeeding
- Note: other protocol defined Exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
July 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04408898
Start Date
July 2 2020
End Date
December 1 2021
Last Update
November 16 2021
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic Phoenix
Phoenix, Arizona, United States, 85054
2
University of California San Diego
San Diego, California, United States, 92093
3
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
4
Karmanos Cancer Insitute
Detroit, Michigan, United States, 48201